Peloton Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Peloton Therapeutics, Inc.
Adjuvant renal cell carcinoma is a potentially lucrative indication for any checkpoint inhibitor; Merck & Co. flagship Keytruda is the first to demonstrate benefit in a Phase III study, although rivals are in pursuit.
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.